SCHEMBL14447573

SCHEMBL14447573

COC(=O)c1cc(Oc2ccccc2)ncn1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.55
RAB9A P51151 5/20 0.55
ALDH1A1 P00352 4/20 0.55
SMN1; SMN2 Q16637 4/20 0.50
MAPT P10636 3/20 0.50
CYP1A2 P05177 2/20 0.50
CYP2C19 P33261 2/20 0.50
CYP2C9 P11712 1/20 0.50
KDR P35968 2/20 0.49
TNNI3K Q59H18 2/20 0.49
KMO O15229 1/20 0.49
L3MBTL1 Q9Y468 2/20 0.48
TDP1 Q9NUW8 1/20 0.48
GAA P10253 1/20 0.47
P2RX3 P56373 1/20 0.45
RECQL P46063 1/20 0.44
LMNA P02545 1/20 0.43
MAPK14 Q16539 1/20 0.43
GLA P06280 1/20 0.43
HPGDS O60760 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12020669 0.87 KMO (0.48) NPC1RAB9AALDH1A1SMN1; SMN2MAPT
SCHEMBL12020692 0.86 MAPT (0.58) NPC1RAB9AALDH1A1SMN1; SMN2MAPT
SCHEMBL13408257 0.85 MAPT (0.51) NPC1RAB9AALDH1A1MAPTKDR
SCHEMBL14447572 0.81 NPC1 (0.57) NPC1RAB9AALDH1A1SMN1; SMN2MAPT
SCHEMBL3716193 0.79 ALDH1A1 (0.48) ALDH1A1MAPTCYP1A2CYP2C19TDP1
SCHEMBL7608437 0.78 MAPT (0.67) NPC1RAB9AALDH1A1SMN1; SMN2MAPT
SCHEMBL31691382 0.78 MEN1 (0.57) NPC1RAB9ASMN1; SMN2KDRTNNI3K
SCHEMBL5319331 0.77 MAP2K7 (0.47) MAPTKDRTNNI3KMAPK14
SCHEMBL5319339 0.77 KDR (0.47) KDRTNNI3KP2RX3MAPK14
SCHEMBL22737611 0.77 GCK (0.56) ALDH1A1KDRTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070155764-A1 NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES KALYPSYS, INC. (US) 2007-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155764-A1 NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES BRAF, ARAF, RAF1 NPC1 4325/4885RAB9A 1640/4885ALDH1A1 3164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.